# Emergent BioSolutions Inc.: financial statements, quarterly

EBS · NYSE · CIK 1367644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ebs.md) · [Financials](/companies/ebs/financials.md) · [Filings](/companies/ebs/filings.md) · [Insiders](/companies/ebs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ebs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [271](/filings/0001367644-24-000178.md) | [277 d](/filings/0001367644-26-000015.md) | [300](/filings/0001367644-25-000124.md) | [255](/filings/0001367644-25-000181.md) | [294](/filings/0001367644-25-000202.md) | [195 d](/filings/0001367644-26-000015.md) | [222](/filings/0001367644-26-000065.md) | [141](/filings/0001367644-26-000082.md) | [231](/filings/0001367644-25-000202.md) | [149 d](/filings/0001367644-26-000015.md) | [156](/filings/0001367644-26-000065.md) | [234](/filings/0001367644-26-000082.md) |
| Cost of revenue | $m | [177](/filings/0001367644-24-000178.md) | [185 d](/filings/0001367644-26-000015.md) | [145](/filings/0001367644-25-000124.md) | [296](/filings/0001367644-25-000181.md) | [123](/filings/0001367644-25-000202.md) | [118 d](/filings/0001367644-26-000015.md) | [88.5](/filings/0001367644-26-000065.md) | [66.9](/filings/0001367644-26-000082.md) | [85.9](/filings/0001367644-25-000202.md) | [84.9 d](/filings/0001367644-26-000015.md) | [72.0](/filings/0001367644-26-000065.md) | [97.1](/filings/0001367644-26-000082.md) |
| Gross profit | $m | [87.2](/filings/0001367644-24-000178.md) | [84.8 d](/filings/0001367644-24-000033.md) | [148](/filings/0001367644-24-000063.md) | [(48.0)](/filings/0001367644-24-000147.md) | [161](/filings/0001367644-24-000178.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [15.3](/filings/0001367644-24-000178.md) | [29.4 d](/filings/0001367644-26-000015.md) | [15.1](/filings/0001367644-25-000124.md) | [32.7](/filings/0001367644-25-000181.md) | [13.8](/filings/0001367644-25-000202.md) | [9.1 d](/filings/0001367644-26-000015.md) | [15.1](/filings/0001367644-26-000065.md) | [12.5](/filings/0001367644-26-000082.md) | [13.5](/filings/0001367644-25-000202.md) | [12.1 d](/filings/0001367644-26-000015.md) | [10.5](/filings/0001367644-26-000065.md) | [9.2](/filings/0001367644-26-000082.md) |
| Selling, general and administrative | $m | [86.0](/filings/0001367644-24-000178.md) | [89.7 d](/filings/0001367644-26-000015.md) | [84.7](/filings/0001367644-25-000124.md) | [85.9](/filings/0001367644-25-000181.md) | [76.6](/filings/0001367644-25-000202.md) | [60.8 d](/filings/0001367644-26-000015.md) | [52.4](/filings/0001367644-26-000065.md) | [43.7](/filings/0001367644-26-000082.md) | [38.9](/filings/0001367644-25-000202.md) | [51.1 d](/filings/0001367644-26-000015.md) | [46.6](/filings/0001367644-26-000065.md) | [44.6](/filings/0001367644-26-000082.md) |
| Operating income | $m | [(242)](/filings/0001367644-24-000178.md) | [(43.8) d](/filings/0001367644-26-000015.md) | [39.8](/filings/0001367644-25-000124.md) | [(204)](/filings/0001367644-25-000181.md) | [64.5](/filings/0001367644-25-000202.md) | [(9.5) d](/filings/0001367644-26-000015.md) | [49.9](/filings/0001367644-26-000065.md) | [1.6](/filings/0001367644-26-000082.md) | [76.5](/filings/0001367644-25-000202.md) | [(27.9) d](/filings/0001367644-26-000015.md) | [10.5](/filings/0001367644-26-000065.md) | [(125)](/filings/0001367644-26-000082.md) |
| Interest expense | $m | [19.7](/filings/0001367644-23-000208.md) | [21.7 d](/filings/0001367644-24-000033.md) | [24.3](/filings/0001367644-24-000063.md) | [23.6](/filings/0001367644-25-000181.md) | [8.3](/filings/0001367644-25-000202.md) | [14.8 d](/filings/0001367644-26-000015.md) | [14.7](/filings/0001367644-26-000065.md) | [14.7](/filings/0001367644-26-000082.md) | [15.2](/filings/0001367644-25-000202.md) | [14.7 d](/filings/0001367644-26-000015.md) | [11.0](/filings/0001367644-26-000065.md) | [10.0](/filings/0001367644-26-000082.md) |
| Income tax | $m | [(2.5)](/filings/0001367644-24-000178.md) | [(5.0) d](/filings/0001367644-26-000015.md) | [3.1](/filings/0001367644-25-000124.md) | [13.3](/filings/0001367644-25-000181.md) | [27.6](/filings/0001367644-25-000202.md) | [3.7 d](/filings/0001367644-26-000015.md) | [24.7](/filings/0001367644-26-000065.md) | [(4.8)](/filings/0001367644-26-000082.md) | [6.4](/filings/0001367644-25-000202.md) | [3.9 d](/filings/0001367644-26-000015.md) | [6.6](/filings/0001367644-26-000065.md) | [13.9](/filings/0001367644-26-000082.md) |
| Net income | $m | [(263)](/filings/0001367644-24-000178.md) | [(49.5) d](/filings/0001367644-26-000015.md) | [9.0](/filings/0001367644-25-000202.md) | [(283)](/filings/0001367644-25-000202.md) | [115](/filings/0001367644-25-000202.md) | [(31.3) d](/filings/0001367644-26-000015.md) | [68.0](/filings/0001367644-26-000082.md) | [(12.0)](/filings/0001367644-26-000082.md) | [51.2](/filings/0001367644-25-000202.md) | [(54.6) d](/filings/0001367644-26-000015.md) | [6.8](/filings/0001367644-26-000082.md) | [(180)](/filings/0001367644-26-000082.md) |
| Diluted EPS | $ per share | [(5.08)](/filings/0001367644-24-000178.md) | not reported | [0.17](/filings/0001367644-25-000124.md) | [(5.38)](/filings/0001367644-25-000181.md) | [2.06](/filings/0001367644-25-000202.md) | not reported | [1.19](/filings/0001367644-26-000065.md) | [(0.22)](/filings/0001367644-26-000082.md) | [0.91](/filings/0001367644-25-000202.md) | not reported | [0.07](/filings/0001367644-26-000065.md) | [(3.49)](/filings/0001367644-26-000082.md) |
| Basic EPS | $ per share | [(5.08)](/filings/0001367644-24-000178.md) | not reported | [0.17](/filings/0001367644-25-000124.md) | [(5.38)](/filings/0001367644-25-000181.md) | [2.16](/filings/0001367644-25-000202.md) | not reported | [1.25](/filings/0001367644-26-000065.md) | [(0.22)](/filings/0001367644-26-000082.md) | [0.96](/filings/0001367644-25-000202.md) | not reported | [0.13](/filings/0001367644-26-000065.md) | [(3.49)](/filings/0001367644-26-000082.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [87.8](/filings/0001367644-24-000178.md) | [112](/filings/0001367644-26-000015.md) | [78.5](/filings/0001367644-25-000124.md) | [69.7](/filings/0001367644-25-000181.md) | [150](/filings/0001367644-25-000202.md) | [99.5](/filings/0001367644-26-000015.md) | [149](/filings/0001367644-26-000065.md) | [267](/filings/0001367644-26-000082.md) | [246](/filings/0001367644-25-000202.md) | [205](/filings/0001367644-26-000082.md) | [160](/filings/0001367644-26-000065.md) | [140](/filings/0001367644-26-000082.md) |
| Current assets | $m | [721](/filings/0001367644-23-000208.md) | [680](/filings/0001367644-25-000021.md) | [682](/filings/0001367644-24-000063.md) | [655](/filings/0001367644-24-000147.md) | [661](/filings/0001367644-24-000178.md) | [599](/filings/0001367644-26-000015.md) | [707](/filings/0001367644-25-000124.md) | [720](/filings/0001367644-25-000181.md) | [787](/filings/0001367644-25-000202.md) | [663](/filings/0001367644-26-000082.md) | [638](/filings/0001367644-26-000065.md) | [666](/filings/0001367644-26-000082.md) |
| Total assets | $m | [1,893](/filings/0001367644-23-000208.md) | [1,823](/filings/0001367644-25-000021.md) | [1,804](/filings/0001367644-24-000063.md) | [1,514](/filings/0001367644-24-000147.md) | [1,478](/filings/0001367644-24-000178.md) | [1,390](/filings/0001367644-26-000015.md) | [1,426](/filings/0001367644-25-000124.md) | [1,417](/filings/0001367644-25-000181.md) | [1,461](/filings/0001367644-25-000202.md) | [1,319](/filings/0001367644-26-000082.md) | [1,320](/filings/0001367644-26-000065.md) | [1,117](/filings/0001367644-26-000082.md) |
| Current liabilities | $m | [664](/filings/0001367644-23-000208.md) | [651](/filings/0001367644-25-000021.md) | [630](/filings/0001367644-24-000063.md) | [620](/filings/0001367644-24-000147.md) | [230](/filings/0001367644-24-000178.md) | [162](/filings/0001367644-26-000015.md) | [112](/filings/0001367644-25-000124.md) | [127](/filings/0001367644-25-000181.md) | [137](/filings/0001367644-25-000202.md) | [132](/filings/0001367644-26-000082.md) | [149](/filings/0001367644-26-000065.md) | [123](/filings/0001367644-26-000082.md) |
| Total liabilities | $m | [1,196](/filings/0001367644-23-000208.md) | [1,174](/filings/0001367644-25-000021.md) | [1,140](/filings/0001367644-24-000063.md) | [1,127](/filings/0001367644-24-000147.md) | [969](/filings/0001367644-24-000178.md) | [907](/filings/0001367644-26-000015.md) | [873](/filings/0001367644-25-000124.md) | [881](/filings/0001367644-25-000181.md) | [879](/filings/0001367644-25-000202.md) | [796](/filings/0001367644-26-000082.md) | [797](/filings/0001367644-26-000065.md) | [775](/filings/0001367644-26-000082.md) |
| Long-term debt | $m | [448](/filings/0001367644-23-000208.md) | [447](/filings/0001367644-25-000021.md) | [447](/filings/0001367644-24-000063.md) | [447](/filings/0001367644-24-000147.md) | [662](/filings/0001367644-24-000178.md) | [664](/filings/0001367644-26-000015.md) | [666](/filings/0001367644-25-000124.md) | [668](/filings/0001367644-25-000181.md) | [663](/filings/0001367644-25-000202.md) | [572](/filings/0001367644-26-000082.md) | [574](/filings/0001367644-26-000065.md) | [582](/filings/0001367644-26-000082.md) |
| Current portion of debt | $m | [414](/filings/0001367644-23-000208.md) | [414](/filings/0001367644-25-000021.md) | [459](/filings/0001367644-24-000063.md) | [415](/filings/0001367644-24-000147.md) | [0.8](/filings/0001367644-24-000178.md) | [0.0](/filings/0001367644-25-000021.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [697](/filings/0001367644-24-000178.md) | [649](/filings/0001367644-26-000015.md) | [664](/filings/0001367644-25-000202.md) | [386](/filings/0001367644-25-000202.md) | [508](/filings/0001367644-25-000202.md) | [483](/filings/0001367644-26-000082.md) | [553](/filings/0001367644-26-000082.md) | [536](/filings/0001367644-26-000082.md) | [583](/filings/0001367644-25-000202.md) | [523](/filings/0001367644-26-000082.md) | [523](/filings/0001367644-26-000082.md) | [341](/filings/0001367644-26-000082.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [60.0 d](/filings/0001367644-24-000178.md) | [32.1 d](/filings/0001367644-26-000015.md) | [(62.6)](/filings/0001367644-25-000124.md) | [47.5 d](/filings/0001367644-25-000181.md) | [154 d](/filings/0001367644-25-000202.md) | [(79.9) d](/filings/0001367644-26-000015.md) | [(11.2)](/filings/0001367644-26-000065.md) | [106 d](/filings/0001367644-26-000082.md) | [(2.3) d](/filings/0001367644-25-000202.md) | [77.7 d](/filings/0001367644-26-000015.md) | [(33.8)](/filings/0001367644-26-000065.md) | [56.1 d](/filings/0001367644-26-000082.md) |
| Capital expenditure | $m | [12.6 d](/filings/0001367644-24-000178.md) | [11.4 d](/filings/0001367644-26-000015.md) | [10.8](/filings/0001367644-25-000124.md) | [4.6 d](/filings/0001367644-25-000181.md) | [5.8 d](/filings/0001367644-25-000202.md) | [1.7 d](/filings/0001367644-26-000015.md) | [3.6](/filings/0001367644-26-000065.md) | [2.9 d](/filings/0001367644-26-000082.md) | [3.4 d](/filings/0001367644-25-000202.md) | [3.9 d](/filings/0001367644-26-000015.md) | [2.4](/filings/0001367644-26-000065.md) | [2.1 d](/filings/0001367644-26-000082.md) |
| Share repurchases | $m | [0.0 d](/filings/0001367644-23-000208.md) | [0.0 d](/filings/0001367644-26-000015.md) | not reported | not reported | [0.0 d](/filings/0001367644-25-000202.md) | [0.0 d](/filings/0001367644-26-000015.md) | [0.0](/filings/0001367644-26-000065.md) | [6.9 d](/filings/0001367644-26-000082.md) | [8.9 d](/filings/0001367644-25-000202.md) | [9.1 d](/filings/0001367644-26-000015.md) | [9.0](/filings/0001367644-26-000065.md) | [9.0 d](/filings/0001367644-26-000082.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.9](/filings/0001367644-23-000208.md) | [50.2](/filings/0001367644-24-000063.md) | [50.7](/filings/0001367644-24-000147.md) | [51.8](/filings/0001367644-24-000178.md) | [52.2](/filings/0001367644-25-000124.md) | [52.6](/filings/0001367644-25-000181.md) | [55.6](/filings/0001367644-25-000202.md) | [57.3](/filings/0001367644-26-000065.md) | [54.2](/filings/0001367644-26-000082.md) | [56.5](/filings/0001367644-25-000202.md) | [56.5](/filings/0001367644-26-000065.md) | [51.6](/filings/0001367644-26-000082.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 51,273,336 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001367644-26-000082.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.